Highlights of weekly biotech stock moves

Amgen Inc. (NASDAQ:AMGN) was off $0.63 to $55.05 on a newsy Friday. The European Commission approved Xgeva denosumab to prevent skeletal-related events in adults with bone metastases from solid tumors.

Meanwhile, the company resolved U.S. patent litigation with Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA), which admitted that its Neutroval (XM02) infringes two U.S. patents covering Amgen's Neupogen filgrastim and agreed not to sell its biologic in the U.S. until after November 2013...